Summary
Global Markets Direct’s, ‘Ionis Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Ionis Pharmaceuticals, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Ionis Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Ionis Pharmaceuticals, Inc.
- The report provides overview of Ionis Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Ionis Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Ionis Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Ionis Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ionis Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ionis Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Ionis Pharmaceuticals, Inc. Snapshot 7
Ionis Pharmaceuticals, Inc. Overview 7
Key Information 7
Key Facts 7
Ionis Pharmaceuticals, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Ionis Pharmaceuticals, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Ionis Pharmaceuticals, Inc. - Pipeline Products Glance 17
Ionis Pharmaceuticals, Inc. - Late Stage Pipeline Products 17
Phase III Products/Combination Treatment Modalities 17
Ionis Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Ionis Pharmaceuticals, Inc. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
Ionis Pharmaceuticals, Inc. - Drug Profiles 22
nusinersen 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
IONIS-463588 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
IONIS-FXIRx 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
IONIS-GCCRRx 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
IONIS-GCGRRx 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
IONIS-PTP1BRx 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ISIS-CRPRx 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
IONIS-APOALRx 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
IONIS-HTTRx 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
IONISDMPK-2.5Rx 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ISIS-EIF4ERx 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ISIS-SOD1Rx 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
IONIS-DGAT2Rx 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
IONIS-HBV-LRx 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
IONIS-HBVRx 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
IONIS-PKKRx 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
IONISGSK-4LRx 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Antisense Oligonucleotide to Inhibit C9ORF72 Protein for Amyotrophic Lateral Sclerosis 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
IONIS-AGTLRx 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
IONIS-TMPRSS6LRx 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
IONISBIIB-4Rx 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
IONISBIIB-5Rx 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
IONISBIIB-6Rx 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ISIS-AATRx 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ISIS-FVIIRx 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ISIS-GHRLRx 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ISIS-RHO2.5Rx 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Antisense Oligonucleotides to Inhibit BCL11A and KLF1 for Hematological Disorders 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Ionis Pharmaceuticals, Inc. - Pipeline Analysis 53
Ionis Pharmaceuticals, Inc. - Pipeline Products by Target 53
Ionis Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 55
Ionis Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 56
Ionis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 57
Ionis Pharmaceuticals, Inc. - Recent Pipeline Updates 59
Ionis Pharmaceuticals, Inc. - Dormant Projects 73
Ionis Pharmaceuticals, Inc. - Discontinued Pipeline Products 74
Discontinued Pipeline Product Profiles 74
ISIS-104838 74
ISIS-113715 74
ISIS-14803 74
ISIS-2503 74
ISIS-5132 75
ISIS-CRPRx 75
ISIS-EIF4ERx 75
Ionis Pharmaceuticals, Inc. - Company Statement 76
Ionis Pharmaceuticals, Inc. - Locations And Subsidiaries 78
Head Office 78
Other Locations & Subsidiaries 78
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80
List of Tables
Ionis Pharmaceuticals, Inc., Key Information 7
Ionis Pharmaceuticals, Inc., Key Facts 7
Ionis Pharmaceuticals, Inc. - Pipeline by Indication, 2016 9
Ionis Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 11
Ionis Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 12
Ionis Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016 13
Ionis Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 14
Ionis Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016 15
Ionis Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 16
Ionis Pharmaceuticals, Inc. - Phase III, 2016 17
Ionis Pharmaceuticals, Inc. - Phase II, 2016 18
Ionis Pharmaceuticals, Inc. - Phase I, 2016 19
Ionis Pharmaceuticals, Inc. - Preclinical, 2016 20
Ionis Pharmaceuticals, Inc. - Discovery, 2016 21
Ionis Pharmaceuticals, Inc. - Pipeline by Target, 2016 53
Ionis Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 55
Ionis Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 56
Ionis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 58
Ionis Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 59
Ionis Pharmaceuticals, Inc. - Dormant Developmental Projects,2016 73
Ionis Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016 74
Ionis Pharmaceuticals, Inc., Subsidiaries 78
List of Figures
Ionis Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016 9
Ionis Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 11
Ionis Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 12
Ionis Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016 13
Ionis Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016 15
Ionis Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016 53
Ionis Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 55
Ionis Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 56
Ionis Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 57
